1. Bukamur H, Katz H, Alsharedi M, et al. Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab. South Med J 2020;113:600–605.
2. Cui P-F, Ma J-X, Wang F-X, et al. Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag 2017;13:1259.
3. Leroy V, Templier C, Faivre J-B, et al. Pembrolizumab-induced pneumonitis. ERJ Open Res 2017;3:00081’2016.
4. Al-dliw M, Megri M, Shahoub I, et al. Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep 2017;22:126–129.
5. Cotliar J, Querfeld C, Boswell WJ, et al. Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2016;2:290.
6. Cousin S, Toulmonde M, Kind M, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol 2016;27:1171–1172.
7. Fakhri G, Akel R, Salem Z, et al. Pulmonary sarcoidosis activation following neoadjuvant pembrolizumab plus chemotherapy combination therapy in a patient with non-small cell lung cancer: a case report. Case Rep Oncol 2017;10:1070–1075.
8. Shannon VR. Pneumotoxicity associated with immune checkpoint inhibitor therapies. Curr Opin Pulm Med 2017;23:305–316.
9. Fragkou P, Souli M, Theochari M, et al. A case of organizing pneumonia (OP) associated with pembrolizumab. Drug Target Insights 2016;10:DTI-S31565.
10. Lee JJX, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma. Acta Oncol 2016;55:519–520.
11. Reungwetwattana T, Adjei AA. Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 2016; 11:2048–2050.
12. Ogawa T, Miyata J, Maehara J, et al. Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC. J Thorac Oncol 2019;14:e9–e10.
13. Sugano T, Seike M, Noro R, et al. A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. Onco Targets Ther 2018;11:5879.
14. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–133.
15. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
16. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006–2017.
17. Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:1607–1616.
18. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–895.
19. Nishino M, Sholl LM, Hatabu H, et al. Anti–PD-1–related pneumonitis during cancer immunotherapy. N Engl J Med 2015;373:288–290.
20. Reuss JE, Kunk PR, Stowman AM, et al. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer 2016;4:94.
21. Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017;152:271–281.
22. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.
23. Tabchi S, Messier C, Blais N. Immune-mediated respiratory adverse events of checkpoint inhibitors. Curr Opin Oncol 2016;28:269–277.
24. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 2014;32(15 suppl):5011.
25. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014;32(15 suppl):3002.
26. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol Off J Am Soc Clin Oncol 2017;35:2781–2789.
27. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837–1846.
28. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–265.
29. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017;377:1919–1929.
30. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342–2350.
31. Garassino MC, Cho B-C, Kim J-H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an openlabel, single-arm, phase 2 study. Lancet Oncol 2018;19:521–536.
32. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17:1374–1385.
33. Brie V, Faure M, Garon J, et al. Drug-induced interstitial pneumonitis due to avelumab: a case report. Rev Mal Respir 2018;35:978–982.
34. Balestra R, Benzaquen S, Wang J. Sarcoidosis-like granulomatous lung reaction associated with anti–programmed death receptor-1 ligand therapy. Ann Am Thorac Soc 2017;14:296–299.
35. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Cancer Netw 2019;17:255–289.